Drugs that contain Dabigatran Etexilate Mesylate

1. Drug name - PRADAXA

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents protects the active chemical substance. Only patent owner can launch products that use this active substance.
US7932273 BOEHRINGER INGELHEIM 3-[(2-{[4-(hexyloxycarbonylaminoiminomethyl) phenylamino]methyl}-1-methyl-1H-benzimidazol-5-carbonyl)pyridin-2-ylamino]propionic acid ethylester methansulfonate and its use as a medicament
Sep, 2025

(2 years from now)

CN102167695B BOEHRINGER INGELHEIM Benzimidazole-Carbonyl-Pyridine-Amino-Ehtyl-Propionate Hemihyrate And Use Thereof
Aug, 2024

(1 year, 10 months from now)

CN1845917A BOEHRINGER INGELHEIM 3 - [(2 - {[4 - (Methoxy Carbonyl Amino-Imino-Methyl) - Phenylamino] - Methyl} - 1-Methyl-1-H-Benzimidazole-5-Carbonyl) - Pyridin-2-Yl-Amino] - Ethyl Propionate-Mesylate And Its Use As A Pharmaceutical
Aug, 2024

(1 year, 10 months from now)

CN1845917B BOEHRINGER INGELHEIM 3 - [(2 - {[4 - (Hexyloxy Carbonyl Amino-Imino-Methyl) - Benzene-Amino] - Methyl} -1--1H - Benzimidazole - -5 - Carbonyl) - Pyridin - -2 - Yl-Amino] - Ethyl Propionate Mesylate And Its Use As A Pharmaceutical
Aug, 2024

(1 year, 10 months from now)

CN102167695A BOEHRINGER INGELHEIM Benzimidazole Carbonyl Pyridine Amino Ethyl Propionate Semihydrate And Application Thereof
Aug, 2024

(1 year, 10 months from now)

IN200600924P1 BOEHRINGER INGELHEIM 3-[(2-{[4-(Hexyloxycarbonylaminoiminomethyl) Phenylamino]Methyl}-1-Methyl-1H-Benzimidazol-5-Carbonyl)Pyridin-2-Ylamino]Propionic Acid Ethylester Methansulfonate And Its Use As A Medicament
Aug, 2024

(1 year, 10 months from now)

IN256941B BOEHRINGER INGELHEIM Process For Preparing 324Hexyloxycarbonyla Minoiminomethylpheny Laminomethyl-1-Methyl-1H-Benzimidazol5Carbon Ylpyridine2Ylaminopro Pionate Methanesulfonate
Aug, 2024

(1 year, 10 months from now)

EP2060569B1 BOEHRINGER INGELHEIM Ethyl 3-[(2-{[4-Hexyloxycarbonylamino-Imino-Methyl)-Phenylamino]-Methyl}-1-Methyl-1H-Benzimidazol-5-Carbonyl)-Pyridin-2-Yl-Amino]-Propionate Methanesulfonate Hemihydrate And Its Use As A Medicament
Aug, 2024

(1 year, 10 months from now)

EP2060569A1 BOEHRINGER INGELHEIM Ethyl 3-[(2-{[4-Hexyloxycarbonylamino-Imino-Methyl)-Phenylamino]-Methyl}-1-Methyl-1H-Benzimidazol-5-Carbonyl)-Pyridin-2-Yl-Amino]-Propionate Methanesulfonate Hemihydrate And Its Use As A Medicament
Aug, 2024

(1 year, 10 months from now)

EP1660482A1 BOEHRINGER INGELHEIM 3-[(2-{ 4-(Hexyloxycarbonylamino-Imino-Methyl)-Phenylamino] -Methyl}-1-Methyl-1H-Benzimidazol-5-Carbonyl)-Pyridin-2-Yl-Amino -Propionic Acid Ethyl Ester Methane Sulphonate And Use Thereof As A Medicament
Aug, 2024

(1 year, 10 months from now)

EP1660482B1 BOEHRINGER INGELHEIM 3-[(2-{ 4-(Hexyloxycarbonylamino-Imino-Methyl)-Phenylamino] -Methyl}-1-Methyl-1H-Benzimidazol-5-Carbonyl)-Pyridin-2-Yl-Amino -Propionic Acid Ethyl Ester Methane Sulphonate And Use Thereof As A Medicament
Aug, 2024

(1 year, 10 months from now)

These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US9925174 BOEHRINGER INGELHEIM Administration form for the oral application of 3-[(2-{[4-(hexyloxycarbonyl-amino-imino-methyl)-phenylamino]-methyl}-1-methyl-1 H-benzimidazol acid ethyl ester and the salts thereof Jun, 2023

(8 months from now)

US9925174

(Pediatric)

BOEHRINGER INGELHEIM Administration form for the oral application of 3-[(2-{[4-(hexyloxycarbonyl-amino-imino-methyl)-phenylamino]-methyl}-1-methyl-1 H-benzimidazol acid ethyl ester and the salts thereof Dec, 2023

(1 year, 2 months from now)

US7932273

(Pediatric)

BOEHRINGER INGELHEIM 3-[(2-{[4-(hexyloxycarbonylaminoiminomethyl) phenylamino]methyl}-1-methyl-1H-benzimidazol-5-carbonyl)pyridin-2-ylamino]propionic acid ethylester methansulfonate and its use as a medicament Mar, 2026

(3 years from now)

US7866474 BOEHRINGER INGELHEIM Film container Aug, 2027

(4 years from now)

US7866474

(Pediatric)

BOEHRINGER INGELHEIM Film container Mar, 2028

(5 years from now)

US9034822 BOEHRINGER INGELHEIM Methods of using antibodies during anticoagulant therapy of dabigatran and/or related compounds Jan, 2031

(8 years from now)

US9034822

(Pediatric)

BOEHRINGER INGELHEIM Methods of using antibodies during anticoagulant therapy of dabigatran and/or related compounds Jul, 2031

(8 years from now)

Treatment: Method of reversing the anticoagulant effect of dabigatran using idarucizumab

Dosage: CAPSULE;ORAL

More Information on Dosage
Strength Dosage Availability
EQ 75MG BASE CAPSULE;ORAL Prescription
EQ 110MG BASE CAPSULE;ORAL Prescription
EQ 150MG BASE CAPSULE;ORAL Prescription

availability in other generic markets.

Click on the highlighted region to filter.